On March 22, 2024, BioNTech SE, which recently named a new CCO, received a notice of default from the NIH concerning royalties and other amounts allegedly owed on sales of the company’s COVID-19 vaccine since commercialization.   A notice of default from the National Institutes of Health (NIH) is a legal step taken against a party that the NIH believes has failed to meet its obligations under a licensing agreement.   BioNTech says it “disagrees with the positions being taken by the NIH...